| Serious adverse events | 4 (2.8) |
| Cardiac perforation needing surgical repair | 1 (0.7) |
| Groin bleeding requiring transfusion | 1 (0.7) |
| Pericardial effusion needing puncture of >500 mL | 1 (0.7) |
| Pneumothorax requiring chest tube | 1 (0.7) |
| Device-related adverse events | 2 (1.4%) |
| LAA perforation (no intervention required) | 2 (1.4%) |
| Minor adverse events within 30 days of LAA ligation | 19 (13.5%) |
| Superficial subxyphoid bleeding | 1 (0.7) |
| Pericardial effusion (two required pericardiocentesis) | 3 (2.1) |
| Pseudoaneurysm (conservative treatment) | 1 (0.7) |
| Pleural effusion (no intervention required) | 4 (2.8) |
| Pneumothorax (no intervention required) | 1 (0.7) |
| Pericarditis greater than 2 days (conservative treatment) | 8 (5.7) |
| Arterio-venous fistula (no intervention required) | 1 (0.7) |
| Serious adverse events | 4 (2.8) |
| Cardiac perforation needing surgical repair | 1 (0.7) |
| Groin bleeding requiring transfusion | 1 (0.7) |
| Pericardial effusion needing puncture of >500 mL | 1 (0.7) |
| Pneumothorax requiring chest tube | 1 (0.7) |
| Device-related adverse events | 2 (1.4%) |
| LAA perforation (no intervention required) | 2 (1.4%) |
| Minor adverse events within 30 days of LAA ligation | 19 (13.5%) |
| Superficial subxyphoid bleeding | 1 (0.7) |
| Pericardial effusion (two required pericardiocentesis) | 3 (2.1) |
| Pseudoaneurysm (conservative treatment) | 1 (0.7) |
| Pleural effusion (no intervention required) | 4 (2.8) |
| Pneumothorax (no intervention required) | 1 (0.7) |
| Pericarditis greater than 2 days (conservative treatment) | 8 (5.7) |
| Arterio-venous fistula (no intervention required) | 1 (0.7) |
LAA, left atrial appendage.
| Serious adverse events | 4 (2.8) |
| Cardiac perforation needing surgical repair | 1 (0.7) |
| Groin bleeding requiring transfusion | 1 (0.7) |
| Pericardial effusion needing puncture of >500 mL | 1 (0.7) |
| Pneumothorax requiring chest tube | 1 (0.7) |
| Device-related adverse events | 2 (1.4%) |
| LAA perforation (no intervention required) | 2 (1.4%) |
| Minor adverse events within 30 days of LAA ligation | 19 (13.5%) |
| Superficial subxyphoid bleeding | 1 (0.7) |
| Pericardial effusion (two required pericardiocentesis) | 3 (2.1) |
| Pseudoaneurysm (conservative treatment) | 1 (0.7) |
| Pleural effusion (no intervention required) | 4 (2.8) |
| Pneumothorax (no intervention required) | 1 (0.7) |
| Pericarditis greater than 2 days (conservative treatment) | 8 (5.7) |
| Arterio-venous fistula (no intervention required) | 1 (0.7) |
| Serious adverse events | 4 (2.8) |
| Cardiac perforation needing surgical repair | 1 (0.7) |
| Groin bleeding requiring transfusion | 1 (0.7) |
| Pericardial effusion needing puncture of >500 mL | 1 (0.7) |
| Pneumothorax requiring chest tube | 1 (0.7) |
| Device-related adverse events | 2 (1.4%) |
| LAA perforation (no intervention required) | 2 (1.4%) |
| Minor adverse events within 30 days of LAA ligation | 19 (13.5%) |
| Superficial subxyphoid bleeding | 1 (0.7) |
| Pericardial effusion (two required pericardiocentesis) | 3 (2.1) |
| Pseudoaneurysm (conservative treatment) | 1 (0.7) |
| Pleural effusion (no intervention required) | 4 (2.8) |
| Pneumothorax (no intervention required) | 1 (0.7) |
| Pericarditis greater than 2 days (conservative treatment) | 8 (5.7) |
| Arterio-venous fistula (no intervention required) | 1 (0.7) |
LAA, left atrial appendage.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
